PARLIAMENTARY WRITTEN QUESTION
(23 February 2026)

To ask the Secretary of State for Health and Social Care, whether data on triple-negative breast cancer is used to identify variation in diagnosis, treatment and outcomes between i) regions and ii) NHS trusts.

Asked by:
Jess Brown-Fuller (Liberal Democrat)

The National Cancer Plan was published on 4 February 2026 and sets out how data will be collected and used to transform healthcare productivity, spot delays, and improve outcomes. This will build directly on the 10-Year Health Plan’s mission to make data the backbone of a modern, responsive National Health Service.

The plan commits to improve cancer waiting times by providing trusts and Cancer Alliances with more granular and actionable data including disaggregated data for specific cancer types, real‑time pathway analytics via the Federated Data Platform, and streamlined cancer metrics to expose unwarranted variation. Trust boards will receive regular performance reports, and clearer public reporting, including more transparent league‑table style data, which will strengthen accountability and drive faster improvement.

Answered by:
()